<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00097006</url>
  </required_header>
  <id_info>
    <org_study_id>1243</org_study_id>
    <nct_id>NCT00097006</nct_id>
  </id_info>
  <brief_title>Retrovirus Epidemiology Donor Study-II (REDS-II)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Heart, Lung, and Blood Institute (NHLBI)</source>
  <brief_summary>
    <textblock>
      To conduct epidemiological, laboratory, and survey research on volunteer blood donors within
      the United States to ensure the safety and availability of the United States' blood supply.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND:

      REDS-I was established to address important blood safety issues involving human retroviruses.
      On July 17, 1989 the NHLBI awarded contracts to five major blood centers and a coordinating
      center to develop a major multicenter epidemiologic study of the human retroviruses HIV-1,
      HIV-2, HTLV-I, and HTLV-II in volunteer U.S. blood donors. The original mission of REDS-I was
      to initiate and facilitate investigations of human retroviruses in volunteer blood donors
      from areas of the country at varying risk for HIV. During the course of the project, NHLBI
      expanded the original REDS-I mission to investigate critical questions posed by the blood
      banking and transfusion medicine communities that were essential to ensuring an adequate
      blood supply without compromising blood safety. The overall REDS-I program includes
      epidemiologic, laboratory, and clinical investigations, and provides a comprehensive
      framework for monitoring U.S. blood donations, and more recently transfusion recipients, for
      infectious disease markers. The operational and database structure of REDS-I, specifically
      designed to study U.S. blood safety and availability, has also provided a framework for rapid
      analytical response to other research questions of significant importance to the safety of
      the blood supply. Since its inception, investigators have made major contributions in
      assessing: the risk of contracting transfusion-transmitted infectious agents; HIV and HCV
      test screening; donor characteristics and behaviors; and ways of reducing HIV risk from
      transfusion. REDS-I investigators work closely with the Food and Drug Administration (FDA),
      Centers for Disease Control and Prevention (CDC) and Office of the Secretary, Department of
      Health and Human Services (DHHS) to provide data and analyses for important policy decisions.
      Liaisons with test manufacturers have enabled the rapid study of test procedures of critical
      importance to blood safety and availability.

      DESIGN NARRATIVE:

      The objectives of the Retrovirus Epidemiology Donor Study-II (REDS-II) are to conduct
      epidemiological, laboratory, and survey research on volunteer blood donors within the United
      States to ensure the safety and availability of the United States' blood supply. This
      includes monitoring known blood-borne infectious agents, rapidly evaluating the impact of
      emerging pathogens, assessing the safety implications of changes in laboratory and/or blood
      donor screening protocols and examining blood supply and availability issues. Addressing
      issues concerned with the safety and availability of the United States' blood supply will be
      the cornerstone of the National Heart, Lung, and Blood Institute's Retrovirus Epidemiology
      Donor Study. These issues include: a) the risks of transfusion-transmissible infections and
      their trends through time--these include infectious agents currently undergoing laboratory
      screening as well as new and emerging agents such as West Nile Virus (WNV) which is about to
      be screened for in the U.S. under experimental protocols; b) ways to reduce the risks of
      transfusion-transmissible infections; c) HIV, HTLV, HCV, and HBV test screening
      methodologies; d) donor characteristics, behaviors, and donation return patterns of U.S.
      blood donors; and e) the effectiveness and safety of various strategies implemented to
      increase the U.S. blood supply.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <condition>Acquired Immunodeficiency Syndrome</condition>
  <condition>Blood Donors</condition>
  <condition>Blood Transfusion</condition>
  <condition>HIV Infections</condition>
  <condition>HIV-1</condition>
  <condition>HIV-2</condition>
  <condition>HTLV-I</condition>
  <condition>HTLV-II</condition>
  <condition>Retroviridae Infections</condition>
  <condition>Hepatitis, Viral, Human</condition>
  <condition>Hepatitis B</condition>
  <condition>Hepacivirus</condition>
  <condition>West Nile Virus</condition>
  <eligibility>
    <criteria>
      <textblock>
        No eligibility criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Busch</last_name>
    <affiliation>Blood Systems Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jerome Gottschall</last_name>
    <affiliation>Blood Center of Southeastern Wisconsin, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christopher Hillyer</last_name>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ram Kakaiya</last_name>
    <affiliation>Institute for Transfusion Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Edward Murphy</last_name>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jorge Rios</last_name>
    <affiliation>American Red Cross Blood Services, New England Region</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ronald Sacher</last_name>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <overall_official>
    <last_name>George Schreiber</last_name>
    <affiliation>Westat, Inc.</affiliation>
  </overall_official>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2004</study_first_submitted>
  <study_first_submitted_qc>November 17, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2004</study_first_posted>
  <last_update_submitted>April 14, 2016</last_update_submitted>
  <last_update_submitted_qc>April 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2016</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>Hepatitis, Viral, Human</mesh_term>
    <mesh_term>Retroviridae Infections</mesh_term>
  </condition_browse>
  <study_docs>
    <study_doc>
      <doc_id>REDS II-CORE</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>http://biolincc.nhlbi.nih.gov/studies/core/</doc_url>
      <doc_comment>NHLBI provides controlled access to IPD through BioLINCC. Access requires registration, evidence of local IRB approval or certification of exemption from IRB review, and completion of a data use agreement.</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>REDS II-CORE</doc_id>
      <doc_type>Manual of Procedures</doc_type>
      <doc_url>http://biolincc.nhlbi.nih.gov/studies/core/</doc_url>
    </study_doc>
    <study_doc>
      <doc_id>REDS II-LAPS</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>http://biolincc.nhlbi.nih.gov/studies/laps/</doc_url>
      <doc_comment>NHLBI provides controlled access to IPD through BioLINCC. Access requires registration, evidence of local IRB approval or certification of exemption from IRB review, and completion of a data use agreement.</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>REDS II-LAPS</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>http://biolincc.nhlbi.nih.gov/studies/laps/</doc_url>
    </study_doc>
    <study_doc>
      <doc_id>REDS II-LAPS</doc_id>
      <doc_type>Study Forms</doc_type>
      <doc_url>http://biolincc.nhlbi.nih.gov/studies/laps/</doc_url>
    </study_doc>
    <study_doc>
      <doc_id>REDS II-LAPS</doc_id>
      <doc_type>Manual of Procedures</doc_type>
      <doc_url>http://biolincc.nhlbi.nih.gov/studies/laps/</doc_url>
    </study_doc>
    <study_doc>
      <doc_id>REDS II-MS</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>http://biolincc.nhlbi.nih.gov/studies/redsms/</doc_url>
      <doc_comment>NHLBI provides controlled access to IPD through BioLINCC. Access requires registration, evidence of local IRB approval or certification of exemption from IRB review, and completion of a data use agreement.</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>REDS II-MS</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>http://biolincc.nhlbi.nih.gov/studies/redsms/</doc_url>
    </study_doc>
    <study_doc>
      <doc_id>REDS II-MS</doc_id>
      <doc_type>Manual of Procedures</doc_type>
      <doc_url>http://biolincc.nhlbi.nih.gov/studies/redsms/</doc_url>
    </study_doc>
    <study_doc>
      <doc_id>REDS II-RISE</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>http://biolincc.nhlbi.nih.gov/studies/rise/</doc_url>
      <doc_comment>NHLBI provides controlled access to IPD through BioLINCC. Access requires registration, evidence of local IRB approval or certification of exemption from IRB review, and completion of a data use agreement.</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>REDS II-RISE</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>http://biolincc.nhlbi.nih.gov/studies/rise/</doc_url>
    </study_doc>
    <study_doc>
      <doc_id>REDS II-RISE</doc_id>
      <doc_type>Study Forms</doc_type>
      <doc_url>http://biolincc.nhlbi.nih.gov/studies/rise/</doc_url>
    </study_doc>
    <study_doc>
      <doc_id>REDS II-RISE</doc_id>
      <doc_type>Manual of Procedures</doc_type>
      <doc_url>http://biolincc.nhlbi.nih.gov/studies/rise/</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

